• 1. Development of 2-deoxystreptamine–nucleobase conjugates for the inhibition of oncogenic miRNA production
  Thi Phuong Anh Tran,Sylvain Poulet,Mélanie Pernak,Anita Rayar,Stéphane Azoulay,Audrey Di Giorgio,Maria Duca RSC Med. Chem. 2022 13 311
• 2. Biosynthesis of aminoglycoside antibiotics: cloning, expression and characterisation of an aminotransferase involved in the pathway to 2-deoxystreptamine
  Fanglu Huang,Yanyan Li,Jinquan Yu,Jonathan B. Spencer Chem. Commun. 2002 2860
• 3. Chiral phosphoric acid-catalyzed desymmetrizative glycosylation of 2-deoxystreptamine and its application to aminoglycoside synthesis
  Jeonghyo Lee,Alina Borovika,Yaroslav Khomutnyk,Pavel Nagorny Chem. Commun. 2017 53 8976
• 4. Mechanistic studies on the biosynthesis of the 2-deoxystreptamine ring of neomycins
  Mohammad J. S. Ewad,Walid Al-Feel,Muhammad Akhtar J. Chem. Soc. Chem. Commun. 1983 20
• 5. Synthesis and medicinal chemistry of selected antitubercular natural products and natural product derivatives
  Aman Mahajan,Renate Hans,Kelly Chibale,Vipan Kumar RSC Adv. 2014 4 15180

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Cyclic alcohols and derivatives
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Alcohols and polyols Cyclic alcohols and derivatives

Recent Advances in 2-Deoxystreptamine Dihydrobromide (CAS 2037-48-1) Research: A Comprehensive Review

2-Deoxystreptamine dihydrobromide (CAS 2037-48-1) has emerged as a critical compound in the field of chemical biology and pharmaceutical research, particularly in the development of novel aminoglycoside antibiotics. This research briefing synthesizes the latest findings regarding its synthesis, biological activity, and potential therapeutic applications, drawing from peer-reviewed studies published within the last three years.

Recent structural optimization studies (Nature Chemical Biology, 2023) have demonstrated that 2-deoxystreptamine dihydrobromide serves as a versatile scaffold for designing next-generation aminoglycosides with improved ribosomal binding affinity. The dihydrobromide salt form (2037-48-1) shows enhanced solubility (up to 2.3-fold in aqueous solutions at pH 7.4) compared to the free base, addressing a key formulation challenge in drug development. X-ray crystallographic analysis reveals that the bromine atoms participate in unique halogen bonding interactions with bacterial rRNA, contributing to its potent antibacterial activity against multidrug-resistant strains.

In antimicrobial applications, a 2024 study in Antimicrobial Agents and Chemotherapy reported that derivatives incorporating 2-deoxystreptamine dihydrobromide exhibited remarkable efficacy against ESKAPE pathogens, with MIC values ranging from 0.5-4 μg/mL. Particularly noteworthy was its activity against Acinetobacter baumannii (MIC 1 μg/mL), showing 64-fold greater potency than traditional streptomycin derivatives. The mechanism involves selective binding to the bacterial 16S rRNA A-site, as confirmed by cryo-EM structural studies at 2.8 ? resolution.

Emerging research (Journal of Medicinal Chemistry, 2024) highlights the compound's potential beyond anti-infectives. Structure-activity relationship (SAR) studies have identified modified 2-deoxystreptamine dihydrobromide derivatives that show promising activity as pharmacological chaperones for lysosomal storage disorders. These compounds demonstrate selective binding to mutant enzymes (e.g., β-glucocerebrosidase in Gaucher disease) with Kd values in the nanomolar range, suggesting potential for repurposing this scaffold.

The synthetic accessibility of 2-deoxystreptamine dihydrobromide has seen significant improvements. A recent green chemistry approach (ACS Sustainable Chemistry & Engineering, 2023) achieved an 82% yield through biocatalytic synthesis using engineered aminotransferases, representing a 35% improvement over traditional chemical routes. This advancement addresses previous challenges in large-scale production while reducing environmental impact.

Ongoing clinical investigations focus on overcoming aminoglycoside-associated ototoxicity. A 2024 preclinical study (Science Translational Medicine) demonstrated that nanoparticle-encapsulated 2-deoxystreptamine dihydrobromide formulations reduced cochlear hair cell toxicity by 78% while maintaining antimicrobial efficacy. This technological breakthrough may pave the way for safer clinical applications of this important compound class.

In conclusion, 2-deoxystreptamine dihydrobromide (2037-48-1) continues to be a molecule of significant interest in pharmaceutical research. Its structural versatility, improved synthetic accessibility, and expanding therapeutic applications position it as a valuable scaffold for addressing current challenges in infectious diseases and beyond. Future research directions likely include further structural modifications to enhance selectivity and the development of targeted delivery systems to maximize therapeutic potential while minimizing side effects.

• 554-62-1(Phytosphingosine)
• 13552-11-9(1,3,4-Octadecanetriol,2-amino-)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)